NYSE: LH · Diagnostics & Research
Labcorp Holdings (LH) fair value and price range
As of 3 Oct 2026, Faircurve's model values Labcorp Holdings (LH) at $307.10 a share. The stock last closed at $308.49, which puts the model's fair value 0.5% below the price. The model grades the evidence behind this valuation as low, so no verdict is shown. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It does not say how likely the fair value is to be right.
Revalued . Price is the close of 2 Oct 2026. Labcorp Holdings Inc.
Faircurve Insights · 3 Oct 2026
Labcorp Holdings, Inc. offers vital diagnostic laboratory services, enabling medical professionals, healthcare facilities, pharmaceutical firms, scientific investigators, and patients to make well-informed and confident choices.
Faircurve's model on 3 Oct 2026 found a fair value of $307.10 a share, the midpoint of 2,000 simulations. The previous run on 26 Sep 2026 gave $307.94, so the fair value moved -0.3%. The calibrated range over 63 trading days is $256.22 to $372.30, built from the fair value since there is no live options data for the stock, calibrated weekly against realised prices (4,809 past valuations, refreshed 3 Oct 2026). Ranges built this way held the price 60% of the time at this horizon. The model grades the evidence behind this valuation as low, so no verdict is shown.
The overall quality score for the company is 48 out of 100, a score against comparable companies. The model compares it with Quest Diagnostics Incorporated (DGX), Mettler-Toledo International Inc. (MTD), Revvity, Inc. (RVTY), Medpace Holdings, Inc. (MEDP), IDEXX Laboratories, Inc. (IDXX), Illumina, Inc. (ILMN), Waters Corporation (WAT), and IQVIA Holdings Inc. (IQV). Moves around the last 8 earnings reports range from +5.8% to -10.0%, with a median size of 2.7%.
Written from the figures on this page for the 3 Oct 2026 valuation and checked by rule before publishing: every number is one printed here, no forecast, no instruction. The price, the gap and the verdict are the page's own and change daily. Not a recommendation.
What price range does the model give LH?
The calibrated range for LH over 63 trading days is $256.22 to $372.30. There is no live options data for this stock, so the range is built from the fair value and calibrated weekly against realised prices (n = 4,809 past valuations, refreshed 3 Oct 2026). Ranges built this way held the price 60% of the time at this horizon.
The model's own simulated range, from the 20th to the 80th percentile of its runs, is $177.07 to $489.42. In 50% of the simulations the fair value came out above the price the model ran on.
How does LH score on business quality?
Labcorp Holdings's overall quality score is 48 out of 100. Each factor below is a score against comparable companies, not a percentile of the metric beside it.
| Factor | Score (0 to 100) | Headline measure | Peer median |
|---|---|---|---|
| ProfitabilityReturn on invested capital against the peer group, with a bonus for an improving trend. | 39 | 8.6%ROIC | 9.1% |
| Earnings qualityHow much of reported profit is cash: free cash flow to net income, and the accrual ratio (the share of earnings that is not cash). | 59 | 1.15xFCF / net income | 1.30x |
| Growth qualityTrailing revenue growth, forward growth from consensus, and the direction of analyst estimate revisions. | 49 | 7.2%Revenue growth, trailing | 8.0% |
| Capital disciplineReinvestment efficiency (capital spending per unit of revenue) and net buybacks. | 80 | 2.8%Net buybacks / market value | 1.5% |
| Balance sheetNet debt to EBITDA and interest coverage. | 35 | 3.08xNet debt / EBITDA | 2.00x |
| StabilityDownside volatility of the EBITDA margin over the last five years. | 28 | 3.0 ptsEBITDA margin downside volatility, 5y | 1.5 pts |
How does LH compare with similar companies?
The companies in diagnostics & research closest to Labcorp Holdings in market value, each on the same model and the same date.
| Company | Last close | Model fair value | Gap | Model verdict |
|---|---|---|---|---|
| DGX Quest Diagnostics Incorporated | $233.33 | $277.32 | +18.9% | Undervalued |
| MTD Mettler-Toledo International Inc. | $1,486.19 | $1,435.21 | -3.4% | Fairly valued |
| RVTY Revvity, Inc. | $151.53 | $149.74 | -1.2% | Fairly valued |
| MEDP Medpace Holdings, Inc. | $599.47 | $647.42 | +8.0% | Fairly valued |
| IDXX IDEXX Laboratories, Inc. | $518.39 | $483.04 | -6.8% | Fairly valued |
| ILMN Illumina, Inc. | $273.04 | $207.94 | -23.8% | Overvalued |
| WAT Waters Corporation | $425.21 | $321.73 | -24.3% | Overvalued |
| IQV IQVIA Holdings Inc. | $258.21 | $342.64 | +32.7% | Undervalued |
All diagnostics & research stocks ranked by gap to fair value
When does LH report earnings, and how has the stock reacted?
Labcorp Holdings's next earnings report is scheduled for 27 Oct 2026. Companies can move their dates.
Options prices on 2 Oct 2026 imply a move of about 8.2% in either direction through the nearest expiry, about 48 days out, a window that includes the report. That is the size the market is pricing, not a direction.
How LH moved around its last 8 earnings reports
Each move runs from the last close before the report to the first close after it, so it covers companies that report before the open and after the close. The median size across these 8 reports, ignoring direction, was 2.7%.
| Report date | Two session move |
|---|---|
| 30 Jul 2026 | +0.7% |
| 30 Apr 2026 | -0.5% |
| 17 Feb 2026 | -1.4% |
| 28 Oct 2025 | -10.0% |
| 24 Jul 2025 | +5.8% |
| 29 Apr 2025 | +5.0% |
| 6 Feb 2025 | -1.5% |
| 24 Oct 2024 | +4.0% |
Labcorp Holdings at a glance
Labcorp Holdings, Inc. offers vital diagnostic laboratory services, enabling medical professionals, healthcare facilities, pharmaceutical firms, scientific investigators, and patients to make well-informed and confident choices.
- Market value
- $25.3B
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Revenue expected, next twelve months
- $15.3B
- Consensus revenue growth, next fiscal year
- +5.7%
- Analysts with estimates
- 10
- Beta to the US market
- 0.21
- First valued by Faircurve
- 1 May 2026
How the fair value is worked out: the model prices Labcorp Holdings on the value of the whole business, debt included, against the operating profit analysts expect next year (forward EV/EBITDA), runs 2,000 simulations across its inputs and takes the midpoint. The full method is documented here.
What changed in the latest valuation?
On 26 Sep 2026 the model's fair value for LH was $307.94. As of 3 Oct 2026 it is $307.10, a change of -0.3%. The model revalues every stock it covers each week, and again after an earnings report.
Questions about Labcorp Holdings's valuation
Is Labcorp Holdings stock undervalued or overvalued?
Faircurve's model puts LH's fair value at $307.10 a share against a last close of $308.49, as of 3 Oct 2026. The model grades the evidence behind this valuation as low, so no verdict is shown. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It does not say how likely the fair value is to be right.
What is LH's fair value?
$307.10 a share as of 3 Oct 2026, the midpoint of 2,000 simulations. The model's own 20th to 80th percentile range is $177.07 to $489.42.
What price range does the model give LH?
$256.22 to $372.30 over 63 trading days. Ranges built this way held the price 60% of the time across 4,809 past valuations, refreshed 3 Oct 2026.
When does Labcorp Holdings report earnings next?
The next report is scheduled for 27 Oct 2026. Companies can move their dates.
How much has LH moved on past earnings reports?
Across its last 8 reports the median two session move was 2.7%, ignoring direction. The largest was -10.0% around the report of 28 Oct 2025.
How confident is the model in this valuation?
The model's evidence grade for LH is low. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It is not a probability that the fair value is right, or that the price reaches it.